# Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

> **NCT00091637** · PHASE3 · COMPLETED · sponsor: **Procter and Gamble** · enrollment: 5745 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** Pexelizumab
- **DRUG:** Placebo infusion

## Key facts

- **NCT ID:** NCT00091637
- **Lead sponsor:** Procter and Gamble
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 5745 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091637, "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00091637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*